Rho-kinase inhibitors

A compound of formula I

• 105
• wherein
• R1 and R2 are each independently
• H, halo, alkyl, optionally substituted by halo up to the perhalo, cycloalkyl, alkenyl, alkynyl, NO2, NH2, NR6R7, or furyl, thienyl, pyridyl, trifluoromethyl or phenyl each optionally substituted with NH2, NO2, trifluoromethyl or alkoxy;
• or
• R1 and R2 may be taken together to form a ring of from 5 to 7 members optionally interrupted by N and optionally substituted on N by benzyl;
• R3 is NH2 or —NH— phenyl optionally substituted with halo, C1-C4 alkyl, trifluoromethyl, nitro or amino;
• R4 is
• 106
• or indol-5-yl (optionally) substituted on the N with pyridyl;
• X is a linker substituted at the 3 or 4 position of the ring and is O,S,—S—CH2—, —(CH2)m—, or —(C=0)—;
• A is phenyl optionally substituted with alkylthio or OH,
• pyridyl,
• quinolyl or
• isoquinolyl;
• each R5 independently is halo, alkyl optionally substituted by halo up to the perhalo level, cycloalkyl, alkoxy, alkenyl, alkynyl, NO2, NH2, or trifluoromethyl;
• n is 0,1,2,3 or 4;
• m is 1 or 2;
• and
• R6 and R7 are each independently H, alkyl, cycloalkyl, or phenyl optionally substituted with halo, CF3, alkyl, nitro or amino;
• or
• R6 and R7 may form, together with the N atom to which they are attached, a heterocyclic ring optionally substituted with alkyl, optionally interrupted by O, or optionally fused to phenyl;
• or a pharmaceutically acceptable salt thereof,
• with the proviso that formula I does not include the following compounds:
• 107 108 109 110 111 112 113 114 115 116 117 118